Dia Beta Labs

Dia Beta Labs, a UK-based biotech company, is dedicated to transforming the treatment landscape for metabolic diseases, particularly diabetes and obesity. With over 30 years of translational research from Ulster University, the company focuses on developing a pipeline of novel peptide therapeutics. These therapeutics are designed to interact with previously untapped receptors on pancreatic beta cells, aiming to halt disease progression by improving beta cell health. Operating in the global healthcare market, Dia Beta Labs addresses the significant challenge posed by the rising prevalence of diabetes and obesity, which affects over 2 billion adults worldwide. The company's business model revolves around the research and development of these innovative therapeutics, potentially generating revenue through partnerships, licensing, and eventual commercialization of their products. By targeting the root causes of metabolic diseases, Dia Beta Labs seeks to offer more effective long-term solutions compared to current antidiabetic medications, which primarily manage blood glucose levels without addressing the progressive loss of insulin-producing beta cells.

Keywords: metabolic disease, diabetes, obesity, peptide therapeutics, beta cells, translational research, healthcare, biotech, UK, Ulster University